Mahima Agochiya, PhD, Business Development & Program Manager, SPARK Translational Research Program, School of Medicine, Stanford University
Mahima Agochiya completed a PhD in Cancer Research, followed by eight years of postdoctoral fellowships in the US, UK and Canada. She also has an MBA in healthcare and has been focused on commercialization of technology in the past 6 years of her career through various positions including her current one as a Business Development Lead at the SPARK program within the Stanford School of Medicine.
Scott C. Brun, MD, Vice President, Corporate Strategy Office Head, AbbVie Ventures
Dr. Brun has worked at Abbott and subsequently AbbVie for over eighteen years in total, beginning his career as the first participant in the Abbott Physician Development Program, a mini-fellowship in pharmaceutical medicine. He has recently taken on the responsibility to lead AbbVie Ventures, where he will work closely with the Chief Strategy Officer to identify and execute on strategic venture investments that are closely aligned with AbbVie’s overall R&D and corporate strategy.
In his previous role, Dr. Brun was the head of Pharmaceutical Development at AbbVie, a 2000+ person global scientific and operational organization responsible for advancing a broad portfolio of early and late stage preregistrational pipeline compounds as well as marketed products within oncology, neurology, immunology, renal, infectious disease, and women’s and men’s health therapeutic areas. Previously, Scott was Divisional Vice President for Infectious Disease Development, where he was responsible for management oversight of multiple Global Project Teams that design and execute early and late stage clinical development programs for Abbott’s Antiviral R&D portfolios, including the marketed products Synagis for prevention of RSV infection in high risk infants, Kaletra and Norvir for the management of HIV infection, and the hepatitis C development pipeline. In the past, Dr. Brun has also directed antimicrobial, renal, and early immunology development programs at Abbott.
Dr. Brun earned his bachelor’s degree in biochemistry from the University of Illinois at Urbana-Champaign. He earned his medical degree from The Johns Hopkins University School of Medicine and completed ophthalmology training at the Massachusetts Eye and Ear Infirmary/Harvard Medical School.
Dr. Brun was part of the 2011 Donalee Tabern Outstanding Research Team at Abbott, recognized for scientific excellence in the area of hepatitis C therapeutics. Crain’s Chicago Business has recognized Dr. Brun in their “40 under 40” professional list. Publications include over 90 abstracts and 20 manuscripts related to antiviral therapeutics.
Rajeev Dadoo, PhD, Partner, S.R. One, Limited
Rajeev joined SR One in 2003 and is an alum of the Kauffman Fellows Program. Rajeev has been involved with SR One’s investments in True North, Illuminoss, Avhana, Setpoint, iPierian, Cydex, Hypnion, Predix and Pinnacle. In addition to his role at SR One, Rajeev spent time with the Competitive Excellence group within GSK working on company-wide strategic projects for GSKs Corporate Executive Team. Prior to SR One, Rajeev worked at Genentech, where his role included technology and clinical development, and at Bio-Rad Laboratories in a product development role. In addition, Rajeev has worked at Genome Therapeutics in the business development role. Rajeev was a co-founder of Unimicro Technologies, a company that was created to develop and commercialize instrumentation for biomedical analysis. Rajeev received his BA degree in Chemistry and Mathematics from Knox College, his MBA from the Wharton School of the University of Pennsylvania, and his PhD in Chemistry from Stanford University.
David H. Donabedian, PhD, Venture Partner, Longwood Fund
Dr. Donabedian is a Venture Partner of the Longwood Fund. In his current role, David supports existing portfolio companies via BoD participation and is responsible for new company formation Dr. Donabedian led Longwood's latest investment in Millendo Therapeutics, Inc. Dr. Donabedian joined Longwood from AbbVie (NASDAQ: ABBV) where, as Vice President & Head of Ventures and Early Stage Collaborations, he led a global team of business development and investment professionals that made minority investments in biotech companies, licensed or acquired preclinical and Phase 1 compounds and created partnerships with leading academic institutions. Prior to AbbVie, Dr. Donabedian was Senior Vice President at Locust Walk Partners a life sciences advisory firm. Previously, Dr. Donabedian was VP Global New Deal Strategy and Development at GlaxoSmithKline (NYSE: GSK). Prior to that, he held management positions at Surface Logix and as a Senior Manager at Accenture’s Strategic Services (NYSE: ACN) Consulting Group. Dr. Donabedian began his career as a research scientist with Dow Chemical and Boston Scientific. He holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Alcyone Life Sciences, a privately held biotech company he co-founded. He is also a strategic advisor to DNATrix.
Patrick Enright, Managing Director, Longitude Capital
Mr. Enright is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund at Diaz & Altschul Capital Management. Mr. Enright began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience including senior executive positions at Valentis (VLTS), Boehringer Mannheim (acquired by Roche) and Sandoz (now known as Novartis). Mr. Enright currently serves on the boards of Aimmune (AIMT), Aptinyx, CardioDx, CrownWheel Partners, InfaCare Pharmaceuticals, Jazz Pharmaceuticals (JAZZ), Orbus Therapeutics and SutroVax. Selected prior board memberships include Codexis (CDXS), Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Horizon Pharmaceuticals (HZNP), MAP Pharmaceuticals (MAPP, acquired by Allergan), Prestwick Pharmaceuticals (acquired by Lundbeck), Sequenom (SQNM, acquired by LabCorp) and Threshold Pharmaceuticals (THLD). Mr. Enright holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.S. in Biological Sciences from Stanford University.
Tao Huang, Ph.D., J.D. Venture Partner, Internal Legal and IP Counsel
Tao has over 20 years of combined experience in biomedical research, legal, and business in academia and the life sciences industry. Prior to Cenova, Tao was an attorney at several prestigious law firms in the US, including Wilson Sonsini Goodrich &Rosati and Morgan Lewis &Bockius. Tao has been advising companies and investors in the biotechnology and pharmaceutical industries on a broad range of business and legal issues, including patent counseling, licensing, litigation, VC financing, M&A and IPO. Tao has provided legal representation to several notable business transactions, including Takeda's licensing and collaboration deal with Alnylam(valued at $1 billion),Ion Torrent's acquisition by Life Technologies ($375 million), and QuantaLife's acquisition by Bio-Rad Laboratories ($162million). Tao received a Ph.D. in Biochemistry from Peking Union Medical College/Chinese Academy of Medical Sciences, a J.D. from the University of Michigan Law School. Tao is a registered United States Patent and Trademark Office attorney in the state of California.
Charlotte Hubbert, PhD, Partner, Gates Foundation Venture Capital
Charlotte Hubbert is a Partner with Gates Foundation Venture Capital, investing in innovative and technologies that support The Bill & Melinda Gates Foundation initiatives in Global Health and Agriculture. Prior to joining the Gates Foundation, Charlotte was a Vice-President at H.I.G. BioVentures focusing on investment opportunities in the life sciences, including therapeutics, diagnostics and medical devices at all stages of development. She was BOD observer at Cardeas Pharma and Alder Biopharmaceuticals. Charlotte started her career in early stage biotech investing at Accelerator Corporation, an investment vehicle focused on identifying, evaluating, financing and managing emerging therapeutic technologies. During her tenure, Charlotte was involved in the strategic development and management of five companies, including Oncofactor, Groove Biopharma, Acylin Therapeutics, Xori and Pharmselex. Charlotte currently serves as an observer on the board of directors of Synlogic, Sera Prognostics and Lodo Therapeutics.
Charlotte earned a B.S. in Microbiology from the University of Washington and a Ph.D. in Pharmacology and Cancer Biology from Duke University. She did her post-doctoral work in stem cells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the University of Washington. Charlotte is a member of the Kauffman Society of Fellows (Class 14).
Jan Hughes, JHBIO Business Development, BioPacific Investors
As the Principal at JHBio Business Development, Jan Hughes serves as a liaison between investors and biopharma/medtech startups, helping each to find the resources they need to move forward. Over her business development career Jan has supported a wide variety of large and small contract and clinical research organizations across the R&D value chain and industry sector.
Additionally, Jan currently serves as the Director of Business Development for BioPacific Investors, an angel investment group created to leverage cross-border opportunities in early stage life science and healthcare. Based in Palo
Alto, CA and Shanghai, BPI focuses on US-based life science and healthcare companies with an AsiaPacific strategic component.
As an active member of the Bay Area life science community, Jan has also served as a Screening Committee and Coach for Springboard Enterprises Health Innovation Hub, 2015-present; Medtech and BioPharma Screening Committees for Life Science Angels, 2008-2009; Board Member, Bio2Device Group, 2015; Pantheon Award Advisory Board, BayBIO, 2008-2014; Program Committee, Clinical Trials and Product Testing, BIO International, 2014. Prior to transitioning into the biopharma/medtech field, Jan enjoyed a long career in veterinary medical sales and sales management.
Jan holds a Bachelor of Arts in English Literature from San Jose State University.
Jennifer Landress, Senior Vice President and Chief Operating Officer, Biocom
Jennifer Landress, CMP, an experienced executive with more than 15 years' experience in budget management, membership, marketing and event development and execution is the Sr. VP and Chief Operating Officer for Biocom. Prior to this she held the position of Vice President of Corporate Relations.
Jennifer oversees the budget, management and goals development for the organization. Additionally, she leads the organization's marketing and events departments to identify opportunities for increased visibility for Southern California life science companies as well as the expansion of the southern California life science community. She is also responsible for Capital Development, Board management, Strategic Planning and the International initiative.
Prior to her employment at Biocom, she was Director of Operations for the Biotechnology Innovation Organization (BIO), the world's largest biotechnology organization with more than 1,200 members worldwide.
Jennifer has a Bachelor of Arts Degree in English from Bucknell University and is a Certified Meeting Professional. She resides in San Diego with her husband, Bo, and three children
John Miller, Chief Executive Officer, Tourette Association of America
John Miller serves as National President & CEO of the Tourette Association of America (TAA), the premier national non-profit organization serving the Tourette Syndrome and Tic Disorder community. In this role, he leverages the organization’s national presence toward making life better for all people affected by Tourette Syndrome and Tic Disorders. Miller is directly involved in the launch and management of a nationwide model of Centers of Excellence, which operate out of our nation’s most prestigious health care and university systems.
To strategically advance the organization and grow its impact, Miller works closely with the Board of Directors; TAA’s robust Nationwide Chapter and Support Network, and the organization’s National Medical, Scientific and Education Advisory Boards comprised of leading experts as well as the Center for Disease Control and Prevention (CDC). As President & CEO, Miller also serves as a key advocate and spokesperson for the Tourette Association and all its constituents.
In recognition of John’s strong leadership, he was named to the inaugural class of the “Kings of Long Island” by the Star Network in 2016. On Twitter: @JohnMillerNY
Julia C. Owens, PhD, President and Chief Executive Officer, Millendo Therapeutics
Dr. Julia C. Owens is the founding President & CEO of Millendo Therapeutics. She has an extensive background in venture-backed biopharmaceutical companies and particular expertise in pharmaceutical company transactions. Prior to co-founding Millendo in 2012, she served as senior vice president, corporate development and strategy at Lycera Corp., where she led the partnering process that led to Lycera's major research partnerships with Merck & Co. Prior to Lycera, Dr. Owens served as head of business development at QuatRx Pharmaceuticals for six years. There, she established several key partnerships, including one with Shionogi for the approved drug, Osphena®. Earlier in her career, Dr. Owens worked at Tularik Inc. (now Amgen San Francisco) in business development for five years, where she led partnering for the oncology and immunology areas, as well as chaired the company's technology acquisition efforts. Dr. Owens began her business career at the University of California, San Francisco Office of Technology Management.
Dr. Owens holds a Ph.D. in biochemistry from the University of California, San Francisco and a B.S. in chemistry and B.A. in molecular and cellular biology from the University of California, Berkeley.
Sara Radcliffe, President and Chief Executive Officer, California Life Science Association (CLSA)
Sara Radcliffe was appointed the president and chief executive officer of the California Life Sciences Association (CLSA) in December 2014. She formerly served as the Executive Vice President for Health at the Biotechnology Industry Organization (BIO). Previously, Sara served as Senior Director, Biologics & Biotechnology at the Pharmaceutical Research and Manufacturers of America (PhRMA). She also served in the Alliance and Technology Group at SmithKline Beecham Pharmaceuticals as a Research and Development Policy Analyst, working on evaluation and communication of the promise, ethics, and impact of rapidly-developing technologies in DNA Research. In addition she worked for the Core Services Committee of the New Zealand Ministry of Health. Sara holds a Master of Public Health and a Master of Arts in Philosophy from the Johns Hopkins University, and a Bachelor of Arts from Wellesley College.
Wendye Robbins, MD, President and Chief Executive Officer, Blade Therapeutics
Wendye is a biopharmaceutical entrepreneur with extensive operational and team building experience. She has made a career of building companies from the ground up. She co-founded early biopharmaceutical companies NeurogesX, Inc. (NASD: NGSX, sold to Acorda Therapeutics), Limerick BioPharma, Labrys Biologics (sold to TEVA 2014), and Blade Therapeutics.
Wendye has functioned as an outside advisor to investors and in this capacity served as development advisor to Rinat Neurosciences, supporting the 2006 Pfizer acquisition. She also managed diligence and development planning to enable spinout of a former Rinat / Pfizer biologic asset into Labrys Biologics. She has been a scientific and strategic advisor to many entrepreneurs, nascent biotechs, and pharmaceutical companies. Her expertise includes small and large molecule development from discovery through translational research through the clinic.
Wendye received her BS from the Haas School of Business, University of California, Berkeley and her MD from the Medical College of Pennsylvania. She completed postgraduate training in internal medicine at the Hospital of the University of Pennsylvania and in anesthesiology and pain at the Johns Hopkins University Medical Institutions. She served as Assistant Professor of Anesthesiology at UCSF from 1995-2000 and has been teaching faculty at the Stanford University School of Medicine since 2002. She is board certified in anesthesiology..
Matthew Roden, PhD, Vice President and Head of Strategic Corporate Development, Bristol-Myers Squibb
Matthew Roden, PhD, is Vice President and Head of Strategic Corporate Development at Bristol-Myers Squibb. In this role, Matt works in close collaboration with leaders across the organization to recommend creative options and proactive strategies to expand the R&D and product portfolio. Matt also oversees the Mergers & Acquisition (M&A) team responsible for acquisitions, structured transactions and divestitures. Prior to joining BMS, Matt was a Senior Equity Analyst and head of the Biotechnology equity research team at UBS, leading coverage of large, mid, and small-cap biotechnology stocks. In this role, Matt strove to be a Street leader in clinical trial analysis, commercial ramp projections, and the regulatory and payer landscape. Earlier, Matt was a Vice President and Senior Biotech analyst at Bank of America Merrill Lynch and J.P. Morgan, the latter of which supported the Institutional Investor #2-ranked large cap biotech franchise. Matt's equity research career started in 2005 at Credit Suisse First Boston as an associate analyst covering biotechnology. Matt holds a PhD in Microbiology and Immunology from the Albert Einstein College of Medicine, and prior was a pre-IRTA Fellow in immuno-oncology at the National Cancer Institute. Matt also holds a M.S. degree from Georgetown University and a B.S. degree from George Mason University.
Lynn Seely, MD, President and Chief Executive Officer, Myovant Sciences
Dr. Seely is an endocrinologist with over 20 years of drug development experience and biopharmaceutical company leadership. At Medivation, she served as Chief Medical Officer from 2005-2015 and led the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer from IND-enabling studies through to NDA approval and post-approval clinical studies. Dr. Seely currently serves on the Board of Directors of Blueprint Medicines Corporation. She completed her residency in internal medicine at Yale-New Haven Hospital and a basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego.
Asish K. Xavier, PhD, Vice President, Venture Investments, Johnson & Johnson Innovation – JJDC, Inc.
Asish is based in the Johnson & Johnson California Innovation Center in Menlo Park, CA. Asish focuses on venture investments in biotechnology and diagnostics. Asish joined JJDC in 2004, and has led or co-led investments in over 20 biotech, diagnostics and medtech deals.
Asish previously worked in business development at BioRexis Pharmaceutical Corporation (King of Prussia, PA) which was acquired by Pfizer in 2007. While at BioRexis, he assisted the company in raising a $30 million round of financing. Asish has worked in business development at Structural GenomiX, Inc. (San Diego, CA), acquired by Eli Lilly in 2008; and, was a project leader at Message Pharmaceuticals, Inc. (Malvern, PA).
Asish received a Ph.D. in Chemical Engineering from the University of Houston and a MBA from the Wharton School of the University of Pennsylvania, where he graduated with honors. He received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. Asish was a postdoctoral research fellow in the Department of Chemistry at the Johns Hopkins University.